Anthera Pharmaceuticals Inc (ANTH.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|2016||Executive Chairman of the Board|
|50||2016||President, Chief Executive Officer, Chief Operating Officer, Director|
|39||2013||Senior Vice President - Finance and Administration, Principal Accounting Officer|
|60||2018||Senior Vice President - Manufacturing|
|68||2016||Chief Medical Officer|
- BRIEF-Anthera Receives Positive Nasdaq Listing Determination
- BRIEF-Anthera Announces Positive Outcome Of Second Interim Futility Analysis In The Phase 3 Sollpura Study
- BRIEF-683 Capital Management Reports 6.1 Pct Passive Stake In Anthera Pharma
- BRIEF-Anthera Pharma Appoints Patrick Murphy As Senior Vice President, Manufacturing
- BRIEF-Anthera Pharmaceuticals Announces Positive Outcome In The Phase 3 Result Clinical Study Of Sollpura